Strain Data Sheet

RBRC11768

Strain Information

Image
BRC No.RBRC11768
TypeCRISPR/Cas9 (Transgene)Cartagena
SpeciesMus musculus
Strain nameB6.Cg-Mapt<em(MAPT/P301S; S320F; Intron10+3 G>A)Tcs>
Former Common nameMAPT P301S; S320F; Intron10+3 G>A mice
H-2 Haplotype
ES Cell lineiTL BA1[(C57BL/6N x 129S6/SvEvTac)F1]
Background strain
Appearance
Strain development
Strain description
Colony maintenance
References
T. C. Saido, Alzheimer's Disease Research Guide: Animal Models for Understanding Mechanisms and Medications.  (Elsevier Inc, Cambridge, MA, 2024).

In vivo hyperphosphorylation of tau is associated with synaptic loss and behavioral abnormalities in the absence of tau seeds.
Naoto Watamura, Martha S Foiani, Sumi Bez, Mathieu Bourdenx, Alessia Santambrogio, Claire Frodsham, Elena Camporesi, Gunnar Brinkmalm, Henrik Zetterberg, Saisha Patel, Naoko Kamano, Mika Takahashi, Javier Rueda-Carrasco, Loukia Katsouri, Stephanie Fowler, Emir Turkes, Shoko Hashimoto, Hiroki Sasaguri, Takashi Saito, Afm Saiful Islam, Seico Benner, Toshihiro Endo, Katsuji Kobayashi, Chiho Ishida, Michele Vendruscolo, Masahito Yamada, Karen E Duff, Takaomi C Saido
Nat. Neurosci. in press (2024). 39719507

Health Report

Examination Date / Room / Rack2025/02/17Room:4-ARack:DSentinel mouse program
2024/11/18Room:4-ARack:DSentinel mouse program

Gene

Gene SymbolGene NameChr.Allele SymbolAllele NameCommon NamesPromoterDiseases Related to This Gene
Frt yeast FRT (flippase recombination target) site11Frt
MAPT microtubule-associated protein tau (human)11MAPT
Mapt
MGI:97180		microtubule-associated protein tau11Mapt<em(MAPT/P301S; S320F; Intron10+3 G>A)Tcs> endonuclease-induced mutation, Takaomi C Saido
  • frontotemporal dementia(DisGeNET, MedGEN)

  • late-onset Parkinson disease(MedGEN)

  • Pick disease(DisGeNET, MedGEN)
    • more 2 Diseases
  • progressive supranuclear palsy-parkinsonism syndrome(MedGEN)

  • supranuclear palsy, progressive, 1(MedGEN)
    • loxP phage P1 loxP11loxP

    Phenotype

    Annotation by Mammalian phenotyhpe ontology
    Detailed phenotype data

    Ordering Information

    Donor DNAhuman MAPT gene, Bacteriophage P1 LoxP site, S.cerevisiae FRT site[S. pyogenes SpCas9*, rat APOBEC1 (apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 1), SV40 NLS, Bacillus subtilis UGI (uracil glycosylase inhibitor): We performed PCR to detect SpCas9, but it was not detected. Other genes were not tested.]
    Research applicationCre/loxP system
    FLP/frt system
    Specific Term and ConditionsThe BIOLOGICAL RESOURCE is the property of the RIKEN (The Institute of Physical and Chemical Research). The RECIPIENT agrees to cite the following literatures in all publications of research results obtained using the BIOLOGICAL RESOURCE. [1] The original paper(s) that describe generation of the BIOLOGICAL RESOURCE. [2]“Alzheimer’s Disease Research Guide: Animal Models for Understanding Mechanisms and Medications” by TC Saido (DOI:10.1016/C2023-0-50891-2). The RECIPIENT does not have to co-author the DEPOSITOR (i.e. TAKAOMI C. SAIDO and other relevant author(s) of the original publication(s)) in their abstract(s)/manuscript(s) unless otherwise specified but agrees to provide the DEPOSITOR with all abstract(s) and manuscript(s), in which the BIOLOGICAL RESOURCE is used, before submission. The RECIPIENT also agrees to acknowledge the DEPOSITOR in all oral presentations and written publications as related to the BIOLOGICAL RESOURCE. Failure to comply with these rules may result in retraction of the RECIPIENT(S)’ abstract(s)/publication(s). The RECIPIENT shall keep confidential any or all information marked CONFIDENTIAL that is received from the DEPOSITOR and related to the BIOLOGICAL RESOURCE including oral discussions if they are reduced to writing within thirty (30) days and are marked "CONFIDENTIAL". For-profit organizations must contact the DEPOSITOR (takaomi.saido@riken.jp) for a licensing contract. If any invention is conceived and reduced to practice by the RECIPIENT in the performance of the Research Plan involving the BIOLOGICAL RESOURCE during the term of this MTA, the RECIPIENT agrees to promptly inform the invention to the DEPOSITOR and the parties will consult each other to determine inventorship and ownership of the invention based on the respective parties’ contribution to the invention, before filing an application for a patent. In the case of a jointly owned application, the parties will separately enter into a joint application agreement including the sharing of ownership, patent costs and licensing income, as well as the responsible party for the application procedures etc.
    DepositorTakaomi C. Saido (RIKEN CBS)
    Strain Statusan icon for Live miceLive mice
    an icon for Frozen embryosFrozen embryos
    an icon for Frozen spermFrozen sperm
    Strain AvailabilityCryopreserved embryos (within 1 month)
    Live mouse (3 to 6 months)
    Additional Info.Necessary documents for ordering:
    1. Order form (Japanese / English)
    2. Category I MTA: CRISPR/Cas9 genome edited bioresources (Japanese / English)
    3. Acceptance of responsibility for living modified organism (Japanese / English)

    BRC mice in Publications

    Morito T, Qi M, Kamano N, Sasaguri H, Bez S, Foiani M, Duff K, Benner S, Endo T, Hama H, Kurokawa H, Miyawaki A, Mizuma H, Sahara N, Shimojo M, Higuchi M, Saido TC, Watamura N.
    Human MAPT knockin mouse models of frontotemporal dementia for the neurodegenerative research community.
    Cell Rep Methods 101024(2025) 40220760